Nutriband Expands Product Development Pipeline for Its AVERSA™ Platform Abuse Deterrence Technology – Form 8-K


Nutriband Inc. Expands Product Development Pipeline for its AVERSA™ Platform Abuse Deterrence Technology

ORLANDO, Fla., January 18, 2022 – Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) announced an expanded product development pipeline for its proprietary transdermal abuse deterrent technology AVERSA™. The AVERSA Abuse Deterrence Technology Platform can be applied to any transdermal patch at risk of abuse, misuse, or accidental exposure. It is based on the incorporation of aversive agents into the patch which do not come into contact with the drug matrix and are not delivered to the skin.

Nutriband’s flagship product is AVERSA Fentanyl, which incorporates abuse deterrent properties into a fentanyl transdermal patch and was recently determined to have a potential market of $80-200 million.1. Based on a preliminary market assessment, Nutriband has identified other attractive markets for transdermal products at risk of abuse, misuse, diversion or accidental exposure that could benefit from its AVERSA technology. Currently marketed transdermal products that have labeled abuse warnings include buprenorphine and methylphenidate and both products have reports of abuse or misuse. These two products, AVERSA Buprenorphine and AVERSA Methylphenidate, will be added to the product development pipeline along with AVERSA Fentanyl.

AVERSA buprenorphine has the potential to be a deterrent version of transdermal buprenorphine, a partial opioid agonist, marketed as Butrans® or its generics, which are indicated for the management of pain severe enough to require daily, 24-hour, long-term opioid treatment and for which alternative treatment options are inadequate.

AVERSA methylphenidate has the potential to be an abuse deterrent version of the transdermal central nervous system (CNS) stimulant methylphenidate, marketed as Daytrana®indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

“We are excited about the opportunity to expand our AVERSA product portfolio, as we believe it has the potential to enhance the profile of transdermal products that include labeled warnings for abuse, misuse, diversion or accidental exposure” , said Jeff Patrick, Pharm.D., chief scientific officer.

“AVERSA is a technology platform that can be deployed in almost any transdermal product that carries the risk of abuse or misuse. Our mission is to reduce the risk profile of these drugs while ensuring their availability to patients who need them,” said Gareth Sheridan, CEO.

The recent announcement of a feasibility agreement with Kindeva Drug Delivery, a global leader in transdermal manufacturing, initiates the development of Nutriband’s lead product, AVERSA Fentanyl. Nutriband’s strategy with the AVERSA platform is to focus first on advancing the technology for transdermal fentanyl and then on using the technology to reduce the risk of abuse of transdermal buprenorphine and methylphenidate.


Healthcare Advances Market Analysis; annual sales peak in the United States about five years after launch.

About Nutriband Inc.

We are primarily engaged in developing a portfolio of transdermal pharmaceuticals. Our lead product in development is an abuse deterrent fentanyl patch incorporating our AVERSA abuse deterrence technology. AVERSA™ Technology can be incorporated into any transdermal patch to deter misuse, abuse, diversion and accidental exposure to drugs with abuse potential.

The Company’s website is Any material contained in or derived from the Company’s websites or any other website does not form part of this press release.

Forward-looking statements

Certain statements contained in this press release, including, without limitation, statements containing the words “believes”, “anticipates”, “expects” and words of similar significance, constitute “forward-looking statements “within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements due to a number of factors, including the Company’s ability to develop its proposed anti-abuse fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain necessary financing to develop products and perform necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to commercialize any product that it could develop in the United States and to obtain any other regulatory authorization the approval necessary to market any product in other countries, including European countries, its ability to market any product that it could develop, its ability to create, support, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competetion; business interruptions; adverse publicity and general international, national and local economic and market conditions and the risks generally associated with an undercapitalized developing company, together with the risks contained under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Form S-1, Form 10-K for the fiscal year ended January 31, 2020, and Forms 10-Q, and other filings by the Company. company with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

For more information contact:

Investor Relations
RedChip Companies
David Gentry
[email protected]
1-800-RED-CHIP (733-2447)


Comments are closed.